Back to News & Events

NIH iCorps: Apply by Nov. 16

Apply for the first cohort of FY2023 by Nov. 16!

The I-Corps™ at NIH Program helps current Phase I SBIR/STTR awardees from the NIH and CDC transition from researcher to entrepreneur.

This 8.5-week training program provides practical guidance from experienced industry professionals that will move you forward on your path toward commercialization. Past participants have written strong SBIR/STTR Phase II applications, won partnerships and investments, and built vast networks in the field.

Apply for the first cohort of FY2023 through the NIH ASSIST platform by 5:00 p.m. your local time on Wednesday, November 16.

Questions? Review the FAQs or contact us if you need help at icorps@mail.nih.gov.

Learn More and Apply: https://sbir.cancer.gov/commercialization/business/icorps

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 3762
                    [post_author] => 3
                    [post_date] => 2021-04-13 18:52:28
                    [post_date_gmt] => 2021-04-13 18:52:28
                    [post_content] => 

DepYmed, Inc., has announced a new financing led by Topspin Fund, L.P. and additional investors for a total of $8.3 million.

Led by former Center for Biotech BioEntrepreneur-in-Residence Andreas Grill, DepYmed is a pharmaceutical company focused on a novel phosphatase inhibition technology platform with potential therapeutic application across multiple different disease including Rett Syndrome, Wilson Disease and Breast Cancer.

Full details of the financing can be found within DepYmed’s news release.

[post_title] => DepYmed Secures $8.3M Financing [post_excerpt] => Led by former Center for Biotech BioEntrepreneur-in-Residence Andreas Grill, DepYmed has announced a new financing led by Topspin Fund, L.P. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => depymed-secures-8-3m-financing [to_ping] => [pinged] => https://depymedinc.com/2021/04/depymed-inc-announces-8-3-million-financing/ [post_modified] => 2021-09-20 16:07:40 [post_modified_gmt] => 2021-09-20 16:07:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3762 [menu_order] => 47 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2060 [post_author] => 3 [post_date] => 2015-12-14 20:06:35 [post_date_gmt] => 2015-12-14 20:06:35 [post_content] => Entrepreneur Derek Brand Selected to Facilitate New Bioscience Ventures STONY BROOK, N.Y. – December 14, 2015 – The Center for Biotechnology at Stony Brook University announced today the appointment of Derek Brand as BioEntrepreneur-In-Residence (B-EIR) for the Long Island Bioscience Hub.  The Long Island Bioscience Hub is a National Institutes of Health-designated Research Evaluation and Commercialization Hub, and represents a partnership between Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory, to commercialize technology emerging from their institutions. Mr. Brand most recently served as Vice President of Business Development at Enumeral Biomedical Corp., which licensed a single cell immunology platform out of MIT and is now a publicly traded biotechnology company with a pipeline of novel immunotherapies in oncology.  In addition to Enumeral, Mr. Brand has held both business and scientific roles at multiple early-stage, venture-backed biomedical startup companies; he has also held commercial leadership roles at GE and the New York Academy of Sciences and presently serves on the advisory board of Allovate LLC, a novel allergy immunotherapy company in NYC. He received his MBA from Babson College and his B.A. in biology from Hamilton College. “I’m excited to take on the role of BioEntrepreneur-in-Residence and looking forward to bringing a diverse array of startup experience to the LIBH community” Mr. Brand stated. “The opportunity to dig in at the earliest stages of innovation with the exceptional scientists at Long Island institutions is a terrific opportunity, and it’s an honor to have been selected.” “Mr. Brand is an excellent addition to the team of entrepreneurs engaged in the B-EIR initiative” Diane Fabel, Director of Operations for the Center for Biotechnology stated. “We are excited to see the positive impact these entrepreneurs will have as new companies are launched within the Hub.” Mr. Brand joins an impressive roster of seven B-EIRs that was expanded in November to include Drs. Brian McCarthy and Gian Luca Araldi. Dr. McCarthy has an extensive background as an investment analyst and as the President and CEO of the startup Influmedix while Dr. Araldi has had a distinguished career in drug discovery within the pharmaceutical industry and as the Founder and Principal of US Pharma Services. LIBH B-EIRs are tasked with identifying technology or technologies from within the partner institutions that will create the foundation for licensing and company formation.  B-EIRs will have the support of the LIBH business and technology development staff, along with external industry advisors to develop successful commercialization strategies, and position the company for SBIR/STTR grant opportunities, and Angel and VC investment. The LIBH can also provide opportunities to access development funding to help advance technologies towards commercialization.  Ultimately, the goal is to foster the creation and growth of new ventures that leverage the exceptional scientific and technological advances taking place at LIBH institutions. [post_title] => Long Island Bioscience Hub Selects Third Bioentrepreneur-In-Residence [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => long-island-bioscience-hub-selects-third-bioentrepreneur-in-residence [to_ping] => [pinged] => [post_modified] => 2016-03-29 20:14:04 [post_modified_gmt] => 2016-03-29 20:14:04 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2060 [menu_order] => 194 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3949 [post_author] => 4 [post_date] => 2022-10-26 16:22:25 [post_date_gmt] => 2022-10-26 16:22:25 [post_content] =>

A new article from CFB Director Dr. Clinton Rubin and colleagues appears in the latest issue of the Journal of Bone and Mineral Research from The American Society for Bone and MIneral Research (ASMBR). The article highlights the ability of low-intensity vibration (LIV) to combat skeletal decline in Duchenne Muscular Dystrophy (DMD) as evaluated in a randomized controlled trial. Read the full article here: https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbm4.10685

"Low-Intensity Vibration Protects the Weight-Bearing Skeleton and Suppresses Fracture Incidence in Boys With Duchenne Muscular Dystrophy: A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial"

[post_title] => A new article from CFB Director in Journal of Bone and Mineral Research [post_excerpt] => "Low-Intensity Vibration Protects the Weight-Bearing Skeleton and Suppresses Fracture Incidence in Boys With Duchenne Muscular Dystrophy: A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial" [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => a-new-article-from-cfb-director-in-journal-of-bone-and-mineral-research [to_ping] => [pinged] => [post_modified] => 2023-07-10 12:41:34 [post_modified_gmt] => 2023-07-10 16:41:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3949 [menu_order] => 14 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 3 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 3762 [post_author] => 3 [post_date] => 2021-04-13 18:52:28 [post_date_gmt] => 2021-04-13 18:52:28 [post_content] =>

DepYmed, Inc., has announced a new financing led by Topspin Fund, L.P. and additional investors for a total of $8.3 million.

Led by former Center for Biotech BioEntrepreneur-in-Residence Andreas Grill, DepYmed is a pharmaceutical company focused on a novel phosphatase inhibition technology platform with potential therapeutic application across multiple different disease including Rett Syndrome, Wilson Disease and Breast Cancer.

Full details of the financing can be found within DepYmed’s news release.

[post_title] => DepYmed Secures $8.3M Financing [post_excerpt] => Led by former Center for Biotech BioEntrepreneur-in-Residence Andreas Grill, DepYmed has announced a new financing led by Topspin Fund, L.P. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => depymed-secures-8-3m-financing [to_ping] => [pinged] => https://depymedinc.com/2021/04/depymed-inc-announces-8-3-million-financing/ [post_modified] => 2021-09-20 16:07:40 [post_modified_gmt] => 2021-09-20 16:07:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3762 [menu_order] => 47 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 282 [max_num_pages] => 94 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

DepYmed Secures $8.3M Financing

More Information

Long Island Bioscience Hub Selects Third Bioentrepreneur-In-Residence

More Information

A new article from CFB Director in Journal of Bone and Mineral Research

More Information